BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 16880939)

  • 1. Chemogenomics: drug discovery's panacea?
    Jacoby E
    Mol Biosyst; 2006 May; 2(5):218-20. PubMed ID: 16880939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery on Target 2006 - CHI's fourth annual event. Chemogenomics: small molecules as biological probes.
    Murphy M
    IDrugs; 2007 Jan; 10(1):30-2. PubMed ID: 17187311
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemogenomics approaches to novel target discovery.
    Gaither LA
    Expert Rev Proteomics; 2007 Jun; 4(3):411-9. PubMed ID: 17552925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current parallel chemistry principles and practice: application to the discovery of biologically active molecules.
    Edwards PJ
    Curr Opin Drug Discov Devel; 2009 Nov; 12(6):899-914. PubMed ID: 19894197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the chemogenomic knowledge space with annotated chemical libraries.
    Savchuk NP; Balakin KV; Tkachenko SE
    Curr Opin Chem Biol; 2004 Aug; 8(4):412-7. PubMed ID: 15288252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemogenomics: structuring the drug discovery process to gene families.
    Harris CJ; Stevens AP
    Drug Discov Today; 2006 Oct; 11(19-20):880-8. PubMed ID: 16997137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating molecular design resources within modern drug discovery research: the Roche experience.
    Stahl M; Guba W; Kansy M
    Drug Discov Today; 2006 Apr; 11(7-8):326-33. PubMed ID: 16580974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advance in the research and discovery of novel drugs based on chemogenomics].
    He BK; Ma ZC; Wang YG; Gao Y
    Yao Xue Xue Bao; 2008 Nov; 43(11):1077-81. PubMed ID: 19239023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic era.
    Dougherty TJ; Miller PF
    IDrugs; 2006 Jun; 9(6):420-2. PubMed ID: 16752312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial informatics in the post-genomics ERA.
    Agrafiotis DK; Lobanov VS; Salemme FR
    Nat Rev Drug Discov; 2002 May; 1(5):337-46. PubMed ID: 12120409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-directed combinatorial library design.
    Zhou JZ
    Curr Opin Chem Biol; 2008 Jun; 12(3):379-85. PubMed ID: 18328830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases.
    Nidhi ; Glick M; Davies JW; Jenkins JL
    J Chem Inf Model; 2006; 46(3):1124-33. PubMed ID: 16711732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversity-oriented synthesis; a spectrum of approaches and results.
    Spandl RJ; Bender A; Spring DR
    Org Biomol Chem; 2008 Apr; 6(7):1149-58. PubMed ID: 18362950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of chemical design tools to transform proteomics data into drug candidates.
    Dean PM; Zanders ED
    Biotechniques; 2002 Mar; Suppl():28-33. PubMed ID: 11906004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning from the data: mining of large high-throughput screening databases.
    Yan SF; King FJ; He Y; Caldwell JS; Zhou Y
    J Chem Inf Model; 2006; 46(6):2381-95. PubMed ID: 17125181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemogenomics in drug discovery.
    Kubinyi H
    Ernst Schering Res Found Workshop; 2006; (58):1-19. PubMed ID: 16708995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era.
    Frye SV
    Chem Biol; 1999 Jan; 6(1):R3-7. PubMed ID: 9889153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hit and lead generation: beyond high-throughput screening.
    Bleicher KH; Böhm HJ; Müller K; Alanine AI
    Nat Rev Drug Discov; 2003 May; 2(5):369-78. PubMed ID: 12750740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When poor solubility becomes an issue: from early stage to proof of concept.
    Stegemann S; Leveiller F; Franchi D; de Jong H; Lindén H
    Eur J Pharm Sci; 2007 Aug; 31(5):249-61. PubMed ID: 17616376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.